SCHEMBL4675680

SCHEMBL4675680

CCc1cc(C(=O)C=C(O)c2nc[nH]n2)n(Cc2ccccn2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 2/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
OPRD1 P41143 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
PPARG P37231 1/20 0.35
BRD4 O60885 1/20 0.35
RAB9A P51151 1/20 0.34
ADRA1D P25100 1/20 0.34
CFTR P13569 1/20 0.34
POLB P06746 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672736 0.91 KDM4E (0.35) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL4673863 0.91 HDAC1 (0.37) KDM4EALDH1A1HPGDSMN1; SMN2KDM4C
SCHEMBL4674862 0.89 ALDH1A1 (0.36) KDM4EALDH1A1HPGDKDM4CADRA1D
SCHEMBL4676096 0.88 ALDH1A1 (0.39) KDM4EALDH1A1SMN1; SMN2HSD17B10OPRD1
SCHEMBL4676963 0.87 KDM4C (0.41) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL4671361 0.86 KDM4C (0.39) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL4673982 0.85 ALDH1A1 (0.39) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL4671193 0.85 USP2 (0.39) KDM4EALDH1A1HPGDTSHRPPARG
SCHEMBL4674731 0.85 KDM4E (0.40) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL4678513 0.84 TP53 (0.40) KDM4EALDH1A1SMN1; SMN2KDM4CPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 DNM1L 4084/4885KDM4E 947/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.